Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADX 629

Next Previous
Drug Profile

ADX 629

Alternative Names: ADX-629

Latest Information Update: 21 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aldeyra Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Antitussives; Antivirals; Hepatoprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Aldehyde inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholic hepatitis; Alcoholism; Allergic asthma; Atopic dermatitis; Cough; Cytokine release syndrome; Lipoid nephrosis; Nephrotic syndrome; Plaque psoriasis; SARS-CoV-2 acute respiratory disease
  • Phase I/II Sjogren-Larsson syndrome

Most Recent Events

  • 19 Dec 2023 Efficacy and adverse events data from a phase II ADRO trial in Atopic dermatitis released by Aldeyra Therapeutics
  • 27 Jun 2023 Efficacy and adverse events data from a phase II trial in Cough released by Aldeyra Therapeutics
  • 21 Apr 2023 Aldeyra plans a phase-II clinical trials in Alcoholic hepatitis in the second half of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top